Literature DB >> 7261416

Pituitary function in prolactinoma. Effect of surgery and postoperative bromocriptine therapy.

R Pelkonen, B Grahne, E Hirvonen, S L Karonen, J Salmi, M Tikkanen, S Valtonen.   

Abstract

Forty-five women and fifteen men with prolactinomas have been treated surgically. Patients with large tumours received pituitary irradiation and postoperative hyperprolactinaemia was treated with bromocriptine. The patients have been followed-up for 6-36 months following the operation. The tumours were larger and the levels of production higher in men as compared with women. All women had amenorrhoea. Galactorrhoea was present in forty-three women but not in the men. After surgery serum prolactin levels fell significantly in all women but remained above normal in thirty-six; prolactin remained high in twelve men. Bromocriptine effectively decreased the postoperative hyperprolactinaemia. The surgical complications were oculomotor nerve paresis in one woman and one man. After surgery six (23%) women developed impaired GH secretion, six (15%) impaired thyroid function, eight (18%) impaired cortisol secretion and five (17%) impaired LH secretion in isolation or combination which had not been present preoperatively. Three patients relapsed. Fifteen women menstruated after surgery and ten began to do so during the subsequent bromocriptine treatment. Thus, menstruation was restored in all six women with microadenomas in sixteen of twenty patients with intrasellar macroadenomas and three of nineteen patients with suprasellar adenomas. The preoperative LH-reserve proved to be an important prognostic indicator. Nine patients, i.e. 50% of patients desiring fertility became pregnant. In the men gonadal function deteriorated in four patients and did not improve in any without testosterone treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7261416     DOI: 10.1111/j.1365-2265.1981.tb00618.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Treatment of prolactinomas with megavoltage radiotherapy.

Authors:  A Grossman; M Besser; J Wass; L Rees
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-30

2.  Hyperprolactinemia and erectile dysfunction.

Authors:  S I Zeitlin; J Rajfer
Journal:  Rev Urol       Date:  2000

3.  Treatment of prolactinomas with megavoltage radiotherapy.

Authors:  A Grossman; B L Cohen; M Charlesworth; P N Plowman; L H Rees; J A Wass; A E Jones; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-14

4.  Operative management of chromophobe pituitary tumour recurrences.

Authors:  S Valtonen; J Salmi
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

5.  Bromocriptine in management of large pituitary tumours.

Authors:  J A Wass; J Williams; M Charlesworth; D P Kingsley; A M Halliday; I Doniach; L H Rees; W I McDonald; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-26

6.  Diagnostic criteria in pituitary tumour recurrence--combined modality of surgery and radiotherapy.

Authors:  F Rauhut; H E Clar; M Bamberg; G Benker; W Grote
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

7.  Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.

Authors:  Xiangming Cai; Junhao Zhu; Jin Yang; Chao Tang; Zixiang Cong; Chiyuan Ma
Journal:  Chin Neurosurg J       Date:  2022-04-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.